GV, Mass General Brigham Ventures and Lonza helped Affinia Therapeutics raise $110m to commercialise work originating at Harvard.

Affinia Therapeutics, a US-based gene therapy developer based on research at Harvard Medical School, completed a $110m series B round on Monday featuring chemicals producer Lonza, internet and technology group Alphabet and healthcare provider Mass General Brigham. EcoR1 Capital and Farallon Capital Management co-led the round, which included investment and financial services group Fidelity’s F-Prime…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.